Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.02
-0.38 (-1.48%)
Nov 5, 2024, 1:19 PM EST - Market open
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CLDX stock have an average target of 64.83, with a low estimate of 37 and a high estimate of 90. The average target predicts an increase of 159.16% from the current stock price of 25.02.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CLDX stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 2 | 3 | 3 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +219.81% | Oct 28, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +179.83% | Oct 7, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $45 | Hold | Initiates | $45 | +79.89% | Sep 30, 2024 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +219.81% | Sep 26, 2024 |
Financial Forecast
Revenue This Year
3.89M
from 6.88M
Decreased by -43.44%
Revenue Next Year
3.23M
from 3.89M
Decreased by -17.11%
EPS This Year
-2.49
from -2.92
EPS Next Year
-3.06
from -2.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.6M | 12.6M | 11.8M | ||
| Avg | 3.9M | 3.2M | 3.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.8% | 223.7% | 264.4% | ||
| Avg | -43.4% | -17.1% | 0.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.34 | -2.46 | -2.32 | ||
| Avg | -2.49 | -3.06 | -3.64 | ||
| Low | -2.77 | -3.48 | -4.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.